Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

GYRE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Gyre Therapeutics, Inc.NASDAQ: GYRE

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $431K fell 86.7% year over year, behind the +252.3% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 21.7% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -86.7% toward the trailing-twelve-month pace of +252.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$431K+112.9% QoQ
Last fiscal yearDec 2025
$25.26M+216.4% YoY
LTMMar 2026
$22.46M+252.3% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-86.7%——
1 year+216.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
25.26M USD
Year-over-year change
+216.4%
4-year CAGR
+15.9%

Net Change in Cash vs competitors

How GYRE compares with its peers on the latest reported figures

  • GYRE's LTM Mar 2026 net change in cash of $22.46M is the 2nd largest of the 4 companies compared; the peer median is $5.27M.
  • Its year-over-year change of +252.3% is the highest of 4, against a peer median of +141.4%.
  • Net change in cash amounts to 19.2% of revenue for GYRE, versus a peer median of 70.3%.
GYRE Competitors Peer median
Net Change in Cash for GYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$69.75M +211.9%+12.7%—
GYREGyre Therapeutics, Inc.LTM Mar 2026$22.46M +252.3%—19.2%
GALTGalectin Therapeutics Inc.LTM Mar 2026$6.68M +141.4%——
SRZNSurrozen, Inc.LTM Mar 2026$5.27M -92.9%—70.3%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding GYRE) $5.27M+141.4%+12.7%70.3%

Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)4.31M(85.48M)17.9M9.88M
Depreciation & Amortization290K1.13M1.11M1.59M2.48M
Deferred Income Tax(3.89M)(838K)(1.16M)(1M)(1.11M)
Stock-Based Compensation3.41M13.37M7.28M831K7.16M
Change in Working Capital483K(7.8M)7.46M(15.69M)(15.55M)
Accounts Receivables1.5M(7.92M)1.3M(9.29M)(11.95M)
Inventory3.88M(879K)1.75M(2.14M)(3.63M)
Accounts Payables500K(112K)192K(245K)13K
Other Working Capital(5.39M)1.11M4.22M(4.02M)17K
Other Non-Cash Items3.89M503K96.68M(7.27M)(1.85M)
Operating Cash Flow(83.76M)10.68M25.89M(3.64M)1.01M
Capital Expenditures(839K)(5M)(8.59M)(3.13M)(1.19M)
Acquisitions (Net)0(1.33M)4.02M(1.69M)30K
Purchases of Investments0(7.48M)(15.74M)(15.47M)0
Sales of Investments49.03M0000
Other Investing Activities0(13K)471K(412K)686K
Investing Cash Flow48.19M(13.81M)(19.76M)(19.88M)(474K)
Debt Repayment(6.7M)0000
Common Stock Issued49.55M00773K25.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.7M001.33M(1.49M)
Financing Cash Flow49.55M02.5M2.1M24.38M
Effect of Forex Changes0(1.89M)(298K)(273K)343K
Net Change in Cash13.99M(5.03M)8.33M(21.7M)25.26M
Free Cash Flow(84.59M)5.68M17.31M(6.77M)(180K)

Gyre Therapeutics, Inc.

NASDAQ:GYRE

Intrinsic Alpha fair value

Locked

Current Price

$4.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.